Abstract | BACKGROUND:
Psoriasis has a negative impact on patients' quality of life. Treatment strategies should address both the cutaneous manifestations of the disease and their impact on quality of life. OBJECTIVES: To evaluate the effect of alefacept on quality of life in 553 patients with chronic plaque psoriasis. METHODS: In this multicentre, double-blind, parallel-groups study, patients were randomized to receive alefacept for two courses, alefacept in course 1 and placebo in course 2, or placebo in course 1 and alefacept in course 2. In each course, alefacept 7.5 mg or placebo was administered once weekly by 30-s intravenous injection for 12 weeks followed by 12 weeks of observation. The Dermatology Life Quality Index (DLQI), Dermatology Quality of Life Scales (DQOLS) and Short Form-36 Health Survey (SF-36) were administered at baseline, 2 weeks after the last dose in both courses, at the beginning of course 2, and at the end of the observation period in both courses. RESULTS: In course 1, alefacept significantly reduced (improved) mean DLQI scores compared with placebo: 4.4 vs. 1.8 at 2 weeks after the last dose (P<0.0001) and 3.4 vs. 1.4 at 12 weeks after the last dose (P<0.001). Patients who received two courses of alefacept experienced additional enhancement of quality of life measures during the second course. Similar results were observed for the DQOLS. The SF-36 survey confirmed that alefacept had no negative impact on general quality of life. CONCLUSIONS:
|
Authors | S R Feldman, A Menter, J Y Koo |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 150
Issue 2
Pg. 317-26
(Feb 2004)
ISSN: 0007-0963 [Print] England |
PMID | 14996104
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dermatologic Agents
- Recombinant Fusion Proteins
- Alefacept
|
Topics |
- Adolescent
- Adult
- Aged
- Alefacept
- Chronic Disease
- Dermatologic Agents
(administration & dosage)
- Double-Blind Method
- Female
- Health Status Indicators
- Health Surveys
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Psoriasis
(drug therapy)
- Quality of Life
- Recombinant Fusion Proteins
(administration & dosage)
- Surveys and Questionnaires
- Treatment Outcome
|